Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
NBOMe-escaline
NBOMe-escaline, also known as escaline-NBOMe or as N-(2-methoxybenzyl)-4-ethoxy-3,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative psychedelic drug of the phenethylamine, scaline, and N-benzylphenethylamine (NBOMe) families. It is the N-(2-methoxybenzyl) derivative of escaline.
The drug acts as a potent serotonin 5-HT2A receptor partial agonist, with an affinity (A2) of 0.537 nM, an activational potency (KP) of 7.08 nM, and an intrinsic activity (Emax) of 48%. As a serotonin 5-HT2A receptor agonist in vitro, it was 7-fold more potent than NBOMe-mescaline, 50-fold more potent than escaline, and 476-fold more potent than mescaline.
NBOMe-escaline was first described in the scientific literature by Heinz Pertz and colleagues by 1999. Along with NBOMe-mescaline, it was one of the first psychedelic N-benzylphenethylamines to be discovered, slightly preceding the publication of 25-NB drugs like 25I-NBOMe by the same group of researchers.
Hub AI
NBOMe-escaline AI simulator
(@NBOMe-escaline_simulator)
NBOMe-escaline
NBOMe-escaline, also known as escaline-NBOMe or as N-(2-methoxybenzyl)-4-ethoxy-3,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative psychedelic drug of the phenethylamine, scaline, and N-benzylphenethylamine (NBOMe) families. It is the N-(2-methoxybenzyl) derivative of escaline.
The drug acts as a potent serotonin 5-HT2A receptor partial agonist, with an affinity (A2) of 0.537 nM, an activational potency (KP) of 7.08 nM, and an intrinsic activity (Emax) of 48%. As a serotonin 5-HT2A receptor agonist in vitro, it was 7-fold more potent than NBOMe-mescaline, 50-fold more potent than escaline, and 476-fold more potent than mescaline.
NBOMe-escaline was first described in the scientific literature by Heinz Pertz and colleagues by 1999. Along with NBOMe-mescaline, it was one of the first psychedelic N-benzylphenethylamines to be discovered, slightly preceding the publication of 25-NB drugs like 25I-NBOMe by the same group of researchers.